Two scientists received a top biomedical research prize for their independent work identifying orexin and its role in narcolepsy.

The prestigious 2026 Albert Lasker Basic Medical Research Award has been conferred upon two pioneers of sleep science, Emmanuel Mignot of the Stanford University School of Medicine and Masashi Yanagisawa of the University of Tsukuba. Their landmark research, conducted independently in the late 1990s, fundamentally altered the medical community’s understanding of sleep-wake regulation. By identifying the neuropeptide orexin—also known as hypocretin—and linking its absence to the neurological disorder narcolepsy, these researchers transitioned the field from a vague descriptive study of sleep to a precise, molecular-level discipline.

The Lasker Award, often considered a precursor to the Nobel Prize, carries a $250,000 honorarium and recognizes the profound, life-altering nature of their discoveries. The formal presentation ceremony, scheduled for September 17, 2026, in New York City, will celebrate not only these two scientists but also the broader field of sleep medicine, which has historically struggled to gain the same level of academic prestige as oncology or immunology.

A Tale of Two Scientific Paths

The journey toward understanding narcolepsy was characterized by two distinct methodologies that converged on the same biological reality. In the mid-1990s, the mechanism behind the disorder remained a total mystery. Narcolepsy, a chronic condition characterized by excessive daytime sleepiness and sudden, involuntary loss of muscle tone—known as cataplexy—affected millions, yet no one knew the cause.

Masashi Yanagisawa approached the problem from a molecular perspective. While at the University of Texas Southwestern Medical Center, he was engaged in an ambitious project to identify the functions of "orphan" G protein-coupled receptors—receptors whose ligands were unknown. In 1998, his team successfully isolated a pair of excitatory neuropeptides from the brain, which he named "orexins" (from the Greek word "orexis," meaning appetite). Through rigorous testing, Yanagisawa observed that mice genetically engineered to lack the orexin gene exhibited a behavior strikingly similar to human narcolepsy, characterized by sudden, sleep-like collapses.

Simultaneously, at Stanford University, Emmanuel Mignot was pursuing an epidemiological and genetic approach. For years, Mignot had been studying canine narcolepsy, specifically focusing on Doberman pinschers and Labradors. Through decades of meticulous genetic mapping, he identified a mutation in a specific gene—the orexin receptor-2 gene—in narcoleptic dogs. This finding served as a crucial bridge between animal models and human pathology. Mignot’s team later analyzed the cerebrospinal fluid of human patients, discovering that while healthy individuals had abundant levels of orexin, it was almost entirely absent in those suffering from narcolepsy. Mignot hypothesized that this deficiency was likely the result of an autoimmune reaction triggered by a viral infection, effectively destroying the orexin-producing neurons in the hypothalamus.

Chronology of a Medical Breakthrough

The timeline of this discovery serves as a masterclass in modern medical research, moving from observation to molecular identification and eventually to therapeutic application.

• 1980s–1990s: Emmanuel Mignot begins his study of hereditary narcolepsy in dogs at Stanford, working to isolate the genetic markers responsible for the disorder.
• 1998: Masashi Yanagisawa publishes the discovery of the orexin peptides, identifying their role in brain signaling and wakefulness.
• 1999: Mignot and his team publish the landmark finding in The Lancet, demonstrating that human narcolepsy is caused by a profound deficiency of orexin in the cerebrospinal fluid.
• 2000s–2010s: Research efforts shift toward identifying how the loss of these neurons occurs, with strong evidence mounting for an autoimmune etiology, possibly triggered by infections like influenza or streptococcus.
• 2018–2022: Pharmaceutical interest surges as the understanding of the orexin system matures. Several companies begin the "race for the orexin agonist," seeking to replace the missing chemical in patients.
• August 2026: The FDA approves Takeda’s oveporexton (Orzeyful), the first true orexin-activating therapy designed specifically to address the root cause of narcolepsy type 1.

Supporting Data and Scientific Impact

The implications of the Mignot-Yanagisawa discovery extend far beyond the treatment of narcolepsy. By uncovering the "master switch" for wakefulness, their work unlocked the potential for a new class of medications.

The orexin system is now understood to be the primary stabilizer of the sleep-wake state. When orexin neurons are active, the brain stays awake and alert. When they go quiet, sleep follows. Because this system is so central to human consciousness, it has become a major target for pharmacology. Conversely to the narcolepsy treatment (which aims to replace or stimulate orexin), researchers have developed "orexin antagonists" to treat insomnia. These drugs effectively "turn off" the wakefulness signal, allowing patients with insomnia to transition into sleep naturally without the sedative side effects of traditional sleeping pills.

According to data from the National Institutes of Health, narcolepsy affects approximately 1 in 2,000 people in the United States. Before the identification of the orexin deficiency, diagnosis was often delayed by years, and treatments were largely symptomatic—relying on stimulants like amphetamines to combat sleepiness. The paradigm shift toward orexin-based therapy offers a more precise, biological approach that addresses the underlying deficit rather than merely masking the symptoms.

Official Responses and Recognition

The scientific community has lauded the Lasker Foundation’s decision to honor these researchers. "I am tremendously honored to receive the 2026 Lasker Award, and particularly delighted to see the prestigious recognition given to the field of sleep science," Yanagisawa stated in an official release. He noted that sleep medicine has often been overlooked in the hierarchy of academic disciplines, despite its fundamental role in human health and neurological stability.

Emmanuel Mignot echoed this sentiment in an interview with Stanford Medicine, emphasizing the rarity of such a breakthrough. "That’s the kind of discovery you make once in your entire life," Mignot said. "It was the most exciting finding because suddenly you knew the cause of a human disease."

The recognition by the Lasker Foundation serves as a validation of the importance of basic, curiosity-driven research. Neither Mignot nor Yanagisawa started their careers with the goal of creating a blockbuster drug; they started with a simple, burning question about why humans sleep and why some individuals cannot stay awake.

Broader Implications for Medicine

The 2026 Lasker Awards also recognized other significant contributions to medicine, highlighting a year of transformative innovation. The Lasker DeBakey Clinical Medical Research Award was presented to Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa for their invention of a bispecific antibody for hemophilia A, a development that has revolutionized the standard of care for blood clotting disorders. Additionally, the Lasker Bloomberg Public Service Award was granted to Michael J. Fox for his tireless advocacy in Parkinson’s disease research, a nod to the vital role of patient-led initiatives in driving scientific funding and awareness.

When viewed collectively, these awards underscore a shift in medical research toward precision and patient-centered outcomes. The work of Mignot and Yanagisawa, in particular, illustrates the power of international collaboration and the necessity of persistence in research. Their legacy will not only be the drugs that now help patients with narcolepsy lead more functional lives, but also the blueprint they provided for future researchers looking to solve the mysteries of the human brain.

As the scientific community gathers in New York this September, the conversation will undoubtedly focus on the "post-orexin" future of sleep medicine. With the FDA approval of oveporexton, the field is entering an era of targeted therapeutics that were considered science fiction only three decades ago. The work of these two scientists stands as a testament to the fact that, when the underlying mechanism of a disease is finally brought to light, the path to a cure—while arduous—becomes clear. Their contribution has not only provided answers to a medical enigma but has also opened a new frontier in the study of human physiology, ensuring that the study of sleep remains at the forefront of modern biomedical advancement for years to come.